RxDoctor Payments Data

Katie Baker, NP

Nurse Practitioner · Mechanicsville, VANPI 1346691862

Payments from drug & device makers

$3,537in general payments, 2019–2025

Across 190 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$387
  • Boston Scientific$323
  • Boehringer Ingelheim$260
  • Amgen$248
  • Pfizer$245
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$240
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$3,537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,537 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$187,448
Medicare patients
924
Services billed
3,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban398$370,841
EntrestoSacubitril/Valsartan199$171,074
XareltoRivaroxaban110$113,389
JardianceEmpagliflozin26$39,170
MultaqDronedarone Hcl21$31,588
Repatha SureclickEvolocumab27$23,750
BrilintaTicagrelor24$19,522
Metoprolol Succinate789$7,745
Ranolazine ErRanolazine45$4,262
Flecainide Acetate122$4,128
Losartan Potassium460$3,237
Nebivolol Hcl54$3,021
Atorvastatin Calcium305$2,777
Amlodipine Besylate522$2,403
Propafenone Hcl ErPropafenone Hcl15$2,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$245$370,841398 claims
NovartisEntresto$387$171,074199 claims
Johnson & JohnsonXarelto$132$113,389110 claims
Boehringer IngelheimJardiance$260$39,17026 claims
Sanofi-aventis U.S. LLCMultaq$98$31,58821 claims
AstraZenecaBrilinta$129$19,52224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Mechanicsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →